Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 917

1.
2.
3.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
4.
5.

Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.

Kornstein SG, Fava M, Jiang Q, Tourian KA.

Psychopharmacol Bull. 2009;42(3):21-35.

PMID:
19752839
6.
7.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA.

Curr Med Res Opin. 2008 Jul;24(7):1877-90. doi: 10.1185/03007990802161923 . Epub 2008 May 27.

PMID:
18507895
9.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
10.

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.

J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu.

PMID:
20797382
11.
12.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.

Int Clin Psychopharmacol. 2008 Sep;23(5):243-53. doi: 10.1097/YIC.0b013e32830cebed.

PMID:
18703933
13.

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.

Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ.

J Clin Psychopharmacol. 2011 Oct;31(5):569-76. doi: 10.1097/JCP.0b013e31822c0a68.

PMID:
21869698
14.

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.

Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B.

Int Clin Psychopharmacol. 2008 Jul;23(4):188-97. doi: 10.1097/YIC.0b013e32830263de.

PMID:
18545056
15.

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.

Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT.

CNS Spectr. 2009 Mar;14(3):144-54. Review.

PMID:
19407711
16.

Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.

Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C.

J Clin Psychopharmacol. 2010 Feb;30(1):18-24. doi: 10.1097/JCP.0b013e3181c94c4d.

PMID:
20075643
17.

Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.

Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ.

J Clin Psychopharmacol. 2010 Jun;30(3):294-9. doi: 10.1097/JCP.0b013e3181dcb594.

PMID:
20473066
18.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
19.
20.

Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.

Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.

Int Clin Psychopharmacol. 2012 Jan;27(1):27-39. doi: 10.1097/YIC.0b013e32834d6f91.

PMID:
22027845

Supplemental Content

Support Center